Moderna, Inc. (MRNA)

NMS – Real Time Price. Currency in USD

67.27

+7.52 (12.59%)

At close: Jun 26, 2026, 4:00 PM EDT

67.19

-0.08 (-0.12%)

After-hours: Jun 26, 2026, 7:59 PM EDT

17.06.2026

Moderna to Host Investor Event - Science Day

CAMBRIDGE, MA / ACCESS Newswire / June 17, 2026 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Science Day at 9:00am ET on Thursday, June 25, 2026. The event will feature an overview of Moderna's research and early development programs, highlighting how the Company's mRNA platform, together with advances in AI and robotics, is accelerating innovation and creating opportunities to expand into new therapeutic areas.

17.06.2026

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

U.S. pharmaceutical company Moderna is interested ‌in investing in production facilities in Germany, with an eye on ⁠plants that its German rival BioNTech plans to close, CEO Stephane Bancel told the German business daily Handelsblatt ‌on ⁠Wednesday.

16.06.2026

Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is jumping again.

16.06.2026

Moderna Strengthens Commercial Strategy As Pipeline Advances

Moderna Inc. (NASDAQ:MRNA) announced changes to its operating model and leadership structure. The biotechnology company is preparing for potential new product launches and advancing a broad pipeline.

16.06.2026

Moderna Surges On This Surprising FDA View For Its mRNA-Based Flu Shot

Moderna stock surged Tuesday after documents posted ahead of a key meeting suggested the FDA would likely approve its flu shot.

16.06.2026

US FDA staff says data may support effectiveness of Moderna's flu vaccine in older adults

The U.S. Food and Drug Administration's ‌staff reviewers said preliminary assessment of Moderna's flu shot data ⁠may support effectiveness in adults 65 years and older.

16.06.2026

Moderna announces executive changes ahead of potential launches

Moderna appointed a new chief commercial officer and widened its president's role to oversee certain franchises, the vaccine maker said on Tuesday, as it ‌prepares for potential product launches over the next couple of years.

Videos

13.02.2026

Neutral

MRNA Starts 2026 Volatile: Examining Rally & Pullback, Outsized Options

04.02.2026

Positive

CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery

22.01.2026

Neutral

Baseline characteristics in Moderna cancer vaccine 'misleading': Leerink's Dr. Mani Foroohar

22.01.2026

Negative

Moderna is curbing investment in vaccine trials due to US backlash

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
MRNA	Barclays	Equal Weight	undefined >> $25	January 28th 2026
MRNA	UBS	Neutral	undefined >> $34	January 7th 2026
MRNA	Jefferies	Hold	undefined >> $30	December 12th 2025
MRNA	Citigroup	Neutral	undefined >> $40	March 13th 2025

Press releases

17.06.2026

Moderna to Host Investor Event - Science Day

16.06.2026

Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028

Dr. Stephen Hoge, President of Moderna, to Assume an Expanded Role With Operational Oversight of the Company's Infectious Disease, Intismeran and Rare Disease Franchises Ester Banque to Join Moderna as Chief Commercial Officer CAMBRIDGE, MA / ACCESS Newswire / June 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to support its short- and long-term business goals. As Moderna executes its long-range plan to become a diversified, multi-modality biotechnology company, the Company is preparing to manage three commercial franchises while advancing a broad mRNA pipeline and investing in Moderna research and early development (mRED).

08.06.2026

Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome

Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1] The INTERCEPT-Lynch trial is part of a scientific collaboration between the University of Oxford and Moderna to advance a novel mRNA approach to cancer prevention OXFORD, UK AND CAMBRIDGE, MA / ACCESS Newswire / June 8, 2026 / The University of Oxford and Moderna, Inc. (NASDAQ:MRNA) today announced a Phase 1/2 study of mRNA-4194, Moderna's investigational mRNA-based cancer vaccine for Lynch Syndrome, has received Medicines and Healthcare products Regulatory Agency (MHRA) authorization in the UK. Lynch syndrome is an inherited condition that increases cancer risk.

02.06.2026

Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™”

eCommerce Powered by FFF Enterprises™ delivers an enhanced ordering experience for Moderna customers. eCommerce Powered by FFF Enterprises™ delivers an enhanced ordering experience for Moderna customers.

Moderna, Inc. (MRNA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Moderna, Inc. (MRNA)

Moderna to Host Investor Event - Science Day

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Moderna Strengthens Commercial Strategy As Pipeline Advances

Moderna Surges On This Surprising FDA View For Its mRNA-Based Flu Shot

US FDA staff says data may support effectiveness of Moderna's flu vaccine in older adults